Pfizer's new acquisition generates billions of dollars from migraine drug
The biotech firm’s migraine drug soared in the latest quarter – even though Pfizer’s acquisition deal has not been finalized.
by christian bundgaard, translated by daniel pedersen
Biohaven, which was acquired by Pfizer for USD 11.6bn in May though the deal won’t be finalized until early 2023, has just released its financial figures for the second quarter reporting soaring sales of migraine drug Nurtec, booking a 57% growth compared to last quarter, industry media Endpoints News reports.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pfizer to acquire migraine firm for over USD 11bn
For subscribers
Pfizer drops phase II-ready NASH candidate
For subscribers
